...Johnson & Johnson's Rybrevant for the treatment of non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) Exon 20 Insertion mutations whose disease has continued to progress following chemotherapy. The bispecific antibody is the first drug to receive this indication. Under the pharmacy benefit, among the most advantaged NSCLC (with EFGR mutations) drugs are Genentech's Tarceva, which holds covered or better status for 73% of all insured lives, and Boehringer Ingelheim's Gilotrif, which holds covered or better status for 71% of lives.
SOURCE: MMIT Analytics, as of 5/24/21
No comments:
Post a Comment